The Pharma Data

JANUARY 31, 2021

(Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).

Immune Response 52

Immune Response Research Therapies Disease 52

Drug Discovery World

APRIL 15, 2023

As the theme, Advancing the Frontiers of Cancer Science and Medicine , suggests, a number of announcements, results and presentations will take place at what is widely considered to be a flagship event for the cancer research community. Here are eight anticipated ‘curtain raisers’ in advance of the event: 1.

Virus 130

Virus Clinical Trials Trials Therapies 130

The Pharma Data

NOVEMBER 10, 2020

P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Oral and nasal administration routes are both physiologic approaches to stimulate the mucosal immune system to induce disease modifying benefits.”.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

DECEMBER 3, 2020

No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

MARCH 9, 2021

The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy 4. Two Phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings 2,3.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

MARCH 8, 2021

The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy 4. Two Phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings 2,3.

Immune Response 52

Immune Response Clinical Trials Trials Treatment 52

The Pharma Data

DECEMBER 13, 2020

Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. CAMBRIDGE, Mass. , 14, 2020 /PRNewswire/ — Synlogic, Inc. Synlogic’s President and Chief Executive Officer.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. The Pfizer?BioNTech

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

JANUARY 17, 2021

The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. HFrEF was formerly known as systolic heart failure.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 23, 2020

Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. . Through week 8, no serious adverse events were reported.

DNA 40

DNA Vaccine Immune Response Clinical Trials 40

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. No serious adverse events related to the vaccine candidates studied were reported. CHENGDU, China , Feb. CHENGDU, China , Feb.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. among adults 65 years of age or older.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

USA (known as MSD outside the United States and Canada), the first set of evaluable patients (n = 8) diagnosed with 2 nd or 3 rd line WT1(+) relapsed or refractory metastatic ovarian cancer demonstrated a disease control rate (the sum of overall response rate and rate of stable disease) of 87.5% Kenilworth, N.J.,

Immune Response 52

Immune Response Clinical Trials Therapies Trials 52

The Pharma Data

OCTOBER 21, 2020

(Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20 for treatment of non-Hodgkin’s lymphoma (NHL). T cell therapy in NHL patients.

FDA 40

FDA Immune Response Engineering Clinical Trials 40

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc. futility analysis). . In the U.S.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 30, 2020

This week, Bloomberg reported companies agreed to slash the prices of 119 new therapies that treat a range of illnesses, including pulmonary disease, lupus, diabetes and cancer. No drug-related serious adverse events have been reported as of today. Top line data are expected in late January or early February 2021.

Immune Response 52

Immune Response Vaccine Clinical Trials Production 52

Drug Target Review

JULY 7, 2023

Approximately three percent of the global population — 240 million people — experience autoantibody diseases, which occur when one’s own body attacks critical organs and tissues. Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

JANUARY 11, 2021

Testing Therapies, Antivirals and Vaccines. Stephane Bancel, chief executive officer of Moderna , speaking at a virtual event by Oddo BHF, a financial service group, said, “We believe there will be protection potentially for a couple of years.” . In clinical trials, it could detect COVID-19 with 90%+ accuracy in about two minutes. .

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

DECEMBER 17, 2020

In the initial 275 patients, rates of adverse events (AEs) were similar among groups. If the therapy proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S. , who require oxygen therapy due to COVID-19, OR. Have chronic kidney disease.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

JULY 23, 2021

Vaccines have been and will remain critical to protecting lives against this devastating disease,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “As a long-term partner to the U.S. government in the fight against this pandemic, we are proud of the impact of vaccination efforts across the country. AUTHORIZED USE IN THE U.S.:

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

DECEMBER 28, 2020

. Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease.

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

Drug Target Review

SEPTEMBER 9, 2024

functions to reset the immune system and potentially provide remission for allergic diseases? 1104 acts upstream in the inflammatory response, targeting one of the first key players: antigen-presenting cells (APCs). In allergic diseases, APCs identify and present unknown antigens to the immune system.

Disease 64

Disease Immune Response Clinical Trials Treatment 64

The Pharma Data

JUNE 24, 2021

Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for use in individuals 12 years of age and older. AUTHORIZED USE IN THE U.S.: The Pfizer?BioNTech

Vaccine 52

Vaccine Clinical Trials Trials FDA 52

The Pharma Data

JANUARY 3, 2021

Preclinical data from our laboratory have shown that the nasal administration of anti-CD3 stimulates Tregs that can suppress inflammation and ameliorate inflammatory diseases. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”. . NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

MAY 12, 2021

New data and analyses to be presented from the pivotal Phase 3 CADENZA and CARDINAL studies of sutimlimab, a first-in-class investigational C1s inhibitor that has the potential to be the first approved treatment for hemolysis in adults with cold agglutinin disease (CAD), a serious and chronic autoimmune hemolytic anemia. May 12 , 2021.

Disease 40

Disease FDA Treatment Therapies 40

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. trial and we look forward to sharing T cell immune response data from the German trial in the near future.”. “It View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

NOVEMBER 1, 2020

Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug. Results from studies, conducted in our laboratory have established that nasal administration of anti-CD3 induces Tregs that can suppress inflammation and ameliorate diseases in animal models. NEW YORK and LONDON, Nov.

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52

The Pharma Data

DECEMBER 27, 2020

(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021. Although our industry has enjoyed many successes lately, those affected by the conditions we are focused on still need better choices.

Therapies 52

Therapies Production Clinical Trials Treatment 52

The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. Observed CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim results.

Vaccine 52

Vaccine Clinical Trials Disease Trials 52

The Pharma Data

JULY 21, 2021

We believe that our mRNA technology can be used to develop vaccine candidates addressing other diseases as well. Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 7, 2021

Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. AUTHORIZED USE IN THE U.S.:

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 11, 2020

Centers for Disease Control and Prevention (CDC), will manage allocation and distribution of the vaccine in the U.S. This will be prioritized according to the populations identified by the CDC’s Advisory Committee on Immunization Practices (ACIP) guidelines. CEO and Co-founder of BioNTech.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Dark Matter Blog

JULY 16, 2021

It also captures what drives me and others like me – the opportunity to create a new class of drugs to address diseases not currently treated effectively, but to do so in a novel way. Along with work on IFN-β protein, which became the multiple sclerosis drug Avonex ® , my team worked extensively on adenovirus-mediated IFN-β gene therapy.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

The Pharma Data

AUGUST 16, 2021

AD, also known as atopic eczema, is a chronic inflammatory skin disorder caused by skin barrier dysfunction and dysregulation of the immune response. Atopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.

Trials 40

Trials Clinical Trials Small Molecule Immune Response 40